As a Canadian/Hungarian/American from Bellingham, WA and in the dynamic realm of medical research, I navigate the global forefront of innovation, specializing in transformative therapies such as Chimeric Antigen Receptor T-cell (CAR-T) treatments, cord blood applications, and the pioneering use of mesenchymal stem cells derived from Wharton’s Jelly. My journey is deeply rooted in biochemistry, providing a solid foundation for my diverse pursuits.

With a Master’s in Biopharmaceutical Regulatory Affairs, I adeptly bridge the gap between groundbreaking science and the intricate regulatory frameworks that govern it. My extensive experience in current Good Manufacturing Practice (cGMP) cell therapy manufacturing ensures that the therapies we develop adhere to the highest standards of quality and safety.

Currently, my research is at the intersection of artificial intelligence and regenerative medicine. I am leveraging AI to design artificial plasmids that incorporate Yamanaka transcription factors—Oct4, Sox2, and Klf4—to reprogram somatic cells into induced pluripotent stem cells (iPSCs). These iPSCs are then utilized to harvest exosomes, which hold immense potential in regenerative therapies.

Beyond the laboratory, I am committed to addressing unmet medical needs through compassionate use requests and facilitating medical tourism. By providing services that navigate these pathways, I aim to make innovative regenerative treatments accessible to patients who need them most.

Through this multifaceted approach, I strive to contribute to the advancement of medical science and the development of therapies that not only push the boundaries of what’s possible but also have a tangible, positive impact on patient outcomes worldwide.